IDEAYA Biosciences, Inc. (IDYA)
NASDAQ: IDYA · Real-Time Price · USD
21.85
+0.12 (0.55%)
Feb 21, 2025, 4:00 PM EST - Market closed
IDEAYA Biosciences Revenue
In the year 2024, IDEAYA Biosciences had annual revenue of $7.00M, down -70.07%. IDEAYA Biosciences had revenue of $7.00M in the quarter ending December 31, 2024, with 78.48% growth.
Revenue (ttm)
$7.00M
Revenue Growth
-70.07%
P/S Ratio
254.95
Revenue / Employee
$56,452
Employees
124
Market Cap
1.91B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
IDYA News
- 9 days ago - IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update - PRNewsWire
- 9 days ago - IDEAYA Announces Further Gilead Sciences Clinical Study Collaboration Evaluating Combination of Trodelvy® and IDE397 in MTAP-Deletion NSCLC - PRNewsWire
- 11 days ago - Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming - Seeking Alpha
- 12 days ago - IDEAYA Biosciences Announces Appointment of Healthcare Investment Banking Veteran Joshua Bleharski as Chief Financial Officer - PRNewsWire
- 22 days ago - IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - PRNewsWire
- 26 days ago - IDEAYA Biosciences to Participate in Upcoming February 2025 Investor Relations Events - PRNewsWire
- 5 weeks ago - IDEAYA Biosciences Announces Participation at the 43rd Annual J.P. Morgan Healthcare Conference and 2025 Corporate Guidance - PRNewsWire
- 7 weeks ago - IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors - PRNewsWire